Fan et al.’s dual PI3K/HDAC inhibitor, BEBT‐908, suppresses multiple tumor types through the upregulation of MHC class I in a STAT1‐dependent manner.[269] This result implies that MHC class I enhancer agents can be used directly in membrane donor tumors or be wrapped in TCMs to act on tumors in patients, and these are potent strategies to boost the efficiency of cancer vaccines. Here, HDAC9 is linked to neoplasm.